327 related articles for article (PubMed ID: 25231928)
21. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
22. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
23. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Katodritou E; Kastritis E; Dalampira D; Delimpasi S; Spanoudakis E; Labropoulou V; Ntanasis-Stathopoulos I; Gkioka AI; Giannakoulas N; Kanellias N; Papadopoulou T; Sevastoudi A; Michalis E; Papathanasiou M; Kotsopoulou M; Sioni A; Triantafyllou T; Daiou A; Papadatou M; Kyrtsonis MC; Pouli A; Kostopoulos I; Verrou E; Dimopoulos MA; Terpos E
Am J Hematol; 2023 May; 98(5):730-738. PubMed ID: 36869876
[TBL] [Abstract][Full Text] [Related]
24. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
25. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
[No Abstract] [Full Text] [Related]
26. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
[TBL] [Abstract][Full Text] [Related]
27. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
28. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
29. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
[TBL] [Abstract][Full Text] [Related]
30. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
Jiang N; Qi C; Trieu Y; Reece D; Chang H
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
[TBL] [Abstract][Full Text] [Related]
31. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
Lionetti M; Musto P; Di Martino MT; Fabris S; Agnelli L; Todoerti K; Tuana G; Mosca L; Gallo Cantafio ME; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omede' P; Morabito F; Tassone P; Boccadoro M; Palumbo A; Neri A
Clin Cancer Res; 2013 Jun; 19(12):3130-42. PubMed ID: 23613318
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
Jin X; Jiang X; Li H; Shen K; Liu S; Chen M; Yang C; Han B; Zhuang J
Acta Haematol; 2024 Apr; ():1-10. PubMed ID: 38626745
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.
Liu X; Wu F; Ye W; Deng J; Zhang M; Zhang C; Yu Q; Cao L; Gan S; Ma J
BMJ Open; 2024 Jan; 14(1):e071548. PubMed ID: 38216195
[TBL] [Abstract][Full Text] [Related]
34. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
Chang H; Qi X; Yeung J; Reece D; Xu W; Patterson B
Leuk Res; 2009 Feb; 33(2):259-62. PubMed ID: 18676019
[TBL] [Abstract][Full Text] [Related]
35. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
36. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
37. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
38. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.
Granell M; Calvo X; Garcia-Guiñón A; Escoda L; Abella E; Martínez CM; Teixidó M; Gimenez MT; Senín A; Sanz P; Campoy D; Vicent A; Arenillas L; Rosiñol L; Sierra J; Bladé J; de Larrea CF;
Haematologica; 2017 Jun; 102(6):1099-1104. PubMed ID: 28255016
[TBL] [Abstract][Full Text] [Related]
40. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
